LENZ THERAPEUTICS, INC. Inactive Instrument
LENZ Therapeutics, Inc. Stock OTC Markets
Equities
GRPH
US52635N1037
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.26 USD | -2.75% |
|
+3.58% | +21.37% |
| Apr. 15 | Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target | MT |
| Apr. 15 | William Blair Starts LENZ Therapeutics With Outperform Rating | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 20.46M | Capitalization | 406M |
|---|---|---|---|---|---|
| Net income 2024 * | -55M | Net income 2025 * | -70M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 19.9 x |
| P/E ratio 2024 * |
-7.28
x | P/E ratio 2025 * |
-6.54
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.31% |
More Fundamentals
* Assessed data
More news
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.01% | 0 M€ | 0.00% | - | |
| 0.00% | 34 M€ | +2.56% | - |
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
| 1st Jan change | Capi. | |
|---|---|---|
| -1.66% | 105B | |
| +3.51% | 97.5B | |
| +1.86% | 22.19B | |
| -16.38% | 21.33B | |
| -8.49% | 18.68B | |
| -42.33% | 16.6B | |
| -20.93% | 14.52B | |
| +5.31% | 14.09B | |
| +21.90% | 10.99B |
- Stock Market
- Equities
- LENZ Stock
- GRPH Stock
